Biopolymeric Nanocarriers of Tamarind Xyloglucan and Chitosan for Sunitinib Delivery: Formulation, Characterization and Cytotoxicity Study

introduction: This study focuses on the development of biopolymeric nanocarriers using tamarind seed-derived xyloglucan and chitosan for the delivery of sunitinib, a tyrosine kinase inhibitor used in cancer treatment. materials and methods: The nanocarriers were prepared by ionic gelation and optimized based on particle size, polydispersity index (PDI), zeta potential, and drug encapsulation efficiency. Characterization was performed using dynamic light scattering (DLS), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR). results: The optimized formulation showed nanoparticles in the size range of 150–200 nm with a narrow PDI and positive zeta potential, indicating good stability. FTIR confirmed successful encapsulation without chemical interaction. In vitro drug release exhibited a biphasic pattern with sustained release up to 48 hours. Cytotoxicity was assessed using the MTT assay on MCF-7 breast cancer cells, showing enhanced cytotoxicity for sunitinib-loaded nanocarriers compared to the free drug, indicating improved uptake and efficacy. discussion: The results suggest that tamarind xyloglucan–chitosan nanocarriers are a promising system for the targeted delivery of hydrophobic anticancer agents. conclusion: This biopolymer-based formulation may enhance therapeutic outcomes and reduce side effects, offering potential for further in vivo studies and clinical applications in breast cancer therapy.